Pengaruh Modifikasi Pola Hidup Medis Dengan Atau Tanpa Metformin Terhadap Kadar Asymmetrical Dimethyl Arginine (ADMA) Pada Penderita Obesitas
1. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged Subcutaneous Abdominal Adipocyte Size, But Not Obesity Itself, Predicts type
II Diabetes Independent of Insulin Resistance. Diabetologia. 43, 1498-1506
2. Hossain P, Kawar B. Obesity and Diabetes in developing world: a growing Chalengge. In : N Engl J Med; 2007; 356:213-15 3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM.
Prevalence of overweight and obesity in the United Stated, 1999-2004. JAMA; 2006; 295 (13): 1549-1555
4. Obesitas, Faktor Resiko Berbagai Penyakit. Anda Obesitas?, Awas Bahaya Mengancam!. Diakses
26 Februari 2014. Tersedia dari nkes.jogjaprov.go.id
5. Sugondo S. Obesitas. Dalam : Buku Ajar Ilmu Penyakit Dalam. Sudoyo AW, Setiyohadi B, Alwi I, dkk (Eds). Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FKUI; 2009; 5;3:1973-83
6. Survey Penyakit Degeneratif di Medan. Laporan Penelitian Kerjasama Subdin Yankes dan Rujukan Din Kes Prop Sumut dengan Departemen IKM/KP/IKK FK USU
7. Misra A, Khurana L. Obesity and the Metabolic Syndrome in Developing Countries. J. Clin. Endocrinol. Metab; 2008 93: s9-s30
8. Adams KF, Schatzkin A, Harris TB, Kipnis B, Mouw T, Ballard-Barbash R et al. Overweight, obesity and mortality in a alarge prospective cohort of persons 50 to 71 years old. N Engl J Med;2000; 355, 763-778
9. Bray. Medical Consequence of Obesitasity. In: J Clin Endocrinol Metab; 2004;89(6):2583-9
10. Roberts MJ, Bodnar LM, Patrick TE, Powers RW. The Role of Obesity in PreeclampsiaPregnancy Hypertens. 2011 January 1; 1(1): 6–16
11. Koc F, Tokac M, Erdem S, Kaya C, Unlu A, Karabag T, et al. Serum Monit, 2010; 16(11): CR536-539
12. Schernthaner G. ADMA, cardiovascular disease, and diabetes. 2008
13. Jan T. Kielstein, Cooke JP. Should We Measure Asymmetric Dimethylarginine in Patients with Coronary Artery Disease?, Clinical Chemistry 2007;53:161-163
14. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M , Adegoke OAJ,
et al.Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia (2006) 49: 351– 359
15. Molitch ME, Fujimoto W, Hammon RF, Knowler WC. The diabetes prevention program and its global implications. In: J Am Soc Nephrol; 2003;14:103-7
16. Alternative Forms of Exercise Training Complementary Therapy in the Prevention and Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009 vol. 22 no. 4 220-225
17. Sugondo S. Obesitas pada Sindroma Metabolik: Penyebab atau akibat. Dalam: Naskah lengkap PIT Penyakit Dalam 2005. Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FKUI; 2005: 83-6
18. Sumiardji G. Prediabetes: Apakah perlu diobati?. Dalam: Naskah Lengkap PIT Ilmu Penyakit Dalam FK USU 2006. Medan; 2006: 113-5
19. Bestermann WH Jr. The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes.
Cardiorenal Med 2011;1:211–219
20. Landim MBP, Filho AC, Chagas ACP. Asymmetric dimethylarginine(ADMA) and endothelial dysfunction: implications for atherogenesis, CLINICS 2009;64(5):471-8
21. Despres JP. Potensial contribution of metformin to management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. In: Diabetes Metab; 2003; 29:6S53-61
22. Vallance P, Leiper J. Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway Arterioscler Thromb Vasc Biol 2004;24;1023-1030
23. Maeda S, Miyaki A, Kumagai H, Eto M, So R, Tanaka K, et al. Lifestyle dimethylarginine level in overweight and obese men. Coronary Artery Disease 2013; 24: 583-88
24. Sibal L, Agarwal1 SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease Current Cardiology Reviews, 2010, 6, 82-90
25. Hariawan KN, Suastika K. Hubungan Kendali Glikemik dengan Asymmetric Dimethylarginine Penderita Diabetes Melitus Tipe 2 Lanjut Usia. Jurnal Penyakit Dalam 2008;9:203-214
26. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine
dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. American Journal of Physiology - Heart and Circulatory Physiology 2007;293: H3227-H3245
27. Bo¨ger RH. The Emerging Role of Asymmetric Dimethylarginine as a NovelCardiovascular Risk Factor. Cardiovascular Research 2003;59: 824–833
28. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between
obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.Metabolism 2004; 53:1574–1579
29. Spoto B, Parlonqo RM, Parlonqo G, Sqro E, Zoccali C. The Enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrol 2007; 20(5): 554-559
30. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight Loss Reduces Circulating Asymmetrical Dimethylarginine Concentrations In Morbidly Obese Women. J Clin. Endocrinol. Metab. 2004;89 ( 12): 6277-6281 31. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S et al.
Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment. J. Clin. Endocrinol. Metab. 2008; 93:82-90
32. Tirtawinata TC. Obesitas dan permasalahannya, dalam Ingin Menjadi Langsing? Penanggulangan Obesitas Secara Terpadu. Jakarta. Badan Penerbit FK UI; 2012:
33. Madani R. Signals from adipose tissue in morbid obesity and effect on depot specific differences.University College London. 2009. Tersedia dari http://discovery.ucl.ac.uk/18917/1/18917.pdf
34. World Health Consultation on Obesity. World Health Organization : Technical Report Serries No. 894 : Obesity ; Preventing and Managing the Global Epidemic.WHO.2000
35. The National Institute of Health. Clinical Guideline on identification, evaluation and the treatment of overweight and obesity in adult.Obes.Res 1998;6:51S
36. Schwart MW, Porte JR. Diabetes, Obesity, and the brain. Science; 2005.307(5708):375-9
37. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P.Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle- aged men and women in eastern Finland. Circulation. 1996;93:1372-1329
38. Desilet RA, Karki SD, Dunican KC. Role of Metformin for weight management in Patients without type 2 diabetes mellitus. In: The Annual of Pharmacotherapy; 2008; 42:817-27
39. Zhang JL, Zheng X, Zou DJ, Qiu JL, Zhao XX, Qin YW. Effect of metformin on weight gain during antihypertensive treatment with a beta blocker in Chinese patients. Am.J.Hypertense. 2009; 22 (8): 884-90
40. Madiyono B, Sastroasmoro S, Ismael S. Perkiraan Besar Sampel dalam Dasar- dasar Metodologi Penelitian Klinis. Jakarta : Sagung Seto 2008;3;16: 302-330
41. PERKENI. Konsensus Pengelolaan Diabetes Melitus Tipe 2 di Indonesia; Jakarta ; 2006
42. Markus A. Neurobiology of Obesitasity. Nat Neurosci.2005;8(5):551
43. Obesity and overweight Accessed: 20th May, 2013 tersedia dari:
44. Jensen MD, Ryan DH, Apovian CM, Ard DJ, Comuzzie GA, Donato KA et al.
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
Circulation.
45. Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D’Amico F.Metformin as
Treatment for Overweight and Obese Adults: A Systematic Review. Ann Fam Med 2005;3:457-461
46. National Institute of Health. The Practical Guide Identification, Evaluation and Treatment of Overweight and Obesity in Adults. 2000
47. National Obesity Observatory.Treating adult obesity through lifestyle change interventions, A briefing paper for commissioners. NHS 2010
48. Manaf A. Effect of Metformin Therapy on Plasma Adiponectin in Obesity with Prediabetes Patient; Laporan Penelitian; 2008
49. Lee A, Morley JE. Metformin Decreases Food Consumption and Induces Weight Loss in Subjects with Obesity Type II non Insulin Dependent Diabetes.
Obes Res ;1998; 6: 47-53
50. Tankova T, Dakovska L, Kirilov G, Koev D. Metformin in The Treatment of Obesity in Subjects With Normal Glucose Tolerance. Rom J Intern 2003; 41: 269-75 51. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E et al.
Metformin Reduces Weight, Centripetal Obesity, Insulin, Leptin and Low Density Lipoprotein Cholesterol in non diabetic, morbidly obese subjects With Body Mass Index Greater Than 30. Metabolism 2001; 50, 856-861
52. Taskiran B, Altun BU, Vardar SA, Demir AM, Karadag CH, Altun A. Effect of Exercise on ADMA Level in Type 2 Diabetes MellitusBalkan Med J 2012; 29: 62-7
53. Gomes VA, Casella-Filho A, Chagas ACP, Tanus-Santos JE. Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome.Nitric Oxide 2008;19:345-50
54. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP et al..Metformin Treatment Lowers Asymmetric Dimethylarginine Concentrations in Patients With Type 2 Diabetes. Metabolism, Vol 51, No 7 (July), 2002: pp 843-846 55. Mclaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven G et al.
Insulin Resistant Women and Fall with Weight Loss. J Clin Endocrinol Metab; 2006; 91: 1896-1900